[Therapeutic action of arginine-thiazolidine-carboxylate (ATCA) as evaluated by liver function tests].
The results of a clinical trial on both tolerance and therapeutic effect of ACTA (Arginine-Thiazolidine-Carboxylate) are reported. Thirty patients were treated wih the drug according to a standard administration scheme: 1,2 g of Arginine-Thiazolidine-Carboxylate per day for 60 days. Statistical evaluation has shown, in comparison with the basal values, highly significant differences at the end of the treatment for the parameters of the so-called "cytolytic syndrome". The concept of membrane-protecting action against lipo-peroxydation, exerted by ATCA is also confirmed by the ultra-structural pictures obtained from bioptic liver specimens.
D000328:Adult; D000368:Aged; D001120:Arginine / Q000627:therapeutic use*; D001706:Biopsy; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000188:drug therapy*; D008111:Liver Function Tests; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D013844:Thiazoles / Q000627:therapeutic use*; D053778:Thiazolidines
D013844:Thiazoles; D053778:Thiazolidines; C020213:arginine thiazolidinecarboxylate; D001120:Arginine
L'effetto terapeutico dell'Arginin-Tiazolidin-Carbossilato (ATCA) all'esame dei tests di epatofunzionalità.